利尿剂及扩血管药物对慢性阻塞性肺病急性发作患者的影响被引量：2

The effection of diuretic and vasodilator on patients with an acute exacerbation of chronic obstructive pulmonary disease

在线阅读下载PDF

导出

摘要目的评价静脉联合应用利尿剂及扩血管药物对于COPD急性发作(AECOPD)患者血浆BNP水平的影响。方法入选20名BNP水平升高的AECOPD患者,经临床证实不存在肺心病,随机分为2组(组Ⅰ及组Ⅱ),每组包含10名患者,在常规AECOPD治疗基础上,Ⅰ组患者加用利尿剂,Ⅱ组患者加用利尿剂及扩血管药物,10例稳定期COPD患者作为对照组。上述患者均于入院时、入院第5天、第10天测定BNP浓度。并测定血常规、血气分析、肺功能等指标。结果AECOPD患者血浆BNP浓度在治疗后明显下降,且Ⅱ组较Ⅰ组患者下降更为明显。且对肺功能、血离子等无明显不良影响。结论 AECOPD患者经利尿剂及扩血管药物治疗后血浆BNP水平迅速下降。且对肺功能、血离子等无明显不良影响。【Objective】 Evaluate the effects of a diuretic and a vasodilator on plasma brain natriuretic peptide（BNP） levels in patients with an acute exacerbation of chronic obstructive pulmonary disease（AECOPD）.【Methods】 20 patients were selected,who had an AECOPD with high plasma BNP but without any clinical evidence of cor pulmonale.They were randomLy divided into two groups,groupⅠandⅡ,each contained 10 patients.In addition to standard treatment for AECOPD,the patients in groupⅠwere treated with a mild diuretic,and those in group Ⅱ were treated with a diuretic and a vasodilator.10 patients with stable COPD were selected as the control group.Plasma BNP concentrations were measured on admission and on the fifth and tenth day after that.Blood routine,arterial blood gas analysis,lung function and other indicators were also determined.【Resluts】Plasma BNP concentrations in patients with AECOPD were decreased significantly after treatment,and this decrease was more striking in group Ⅱ than in group Ⅰ,without obvious adverse effect on lung function and blood ions.【Conclusion】Plasma BNP levels in patients with an AECOPD decreased rapidly after therapy with a diuretic and a vasodilator,and without obvious adverse effect on lung function and blood ions.

作者张军何晓雨余晓凌郑国峰潘晓明

机构地区中国医科大学附属第四医院呼吸内科

出处《中国医学工程》 2013年第1期4-6,共3页 China Medical Engineering

关键词脑钠肽慢性阻塞性肺病利尿剂扩血管药 brain natriuretic peptide COPD diuretic vasodilator

分类号 R563 [医药卫生—呼吸系统]

作者简介通讯作者：张军，E—mail：cnzhangjun655@hotmail．com。

引文网络
相关文献

参考文献17

1Pauwels RA,Rabe KF.Burden and clinical features of chronic obstructive pulmonary disease (COPD) [J].Lancet.2004,364: 613- 620.
2Donaldson GC, Wedzicha JA.COPD exacerbations[J].Epidemiology Thorax,2006,61: 164-168.
3Wedzicha JA, Calverley PM, Seemungal TA, et al.The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/ fluticasone propionate or tiotropium bromide[J].Am J Respir Crit Care Med,2008,177: 19-26.
4Global initiatives for chronic obstructive lung disease.Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2006, NHL/II/WHO workshop report Bethesda,national Heart, Lung and Blood institute ,2008.
5Cabanes L, Richaud-Thiriez B, Fulla Y, et al.Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea[J]. Chest,2001,120:2047-2050.
6Maeda K,Tsutamoto T, Wada A,et al.Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction[J]. A m Heart i 1998.135:825-832.
7Battencourt P.NT-proBNP and BNP:biomarkers for heart failure management[J].Eur J Heart Fail,2004,6: 359-363.
8Yap LB,Mukerjee D,Timms PM.Natriuretic peptides[J].respiratory disease,and the right heart,2004,126:1330-1336.
9Lang CC,Coutie WJ,Struthers AD,et al.Elevated levels of brain natriuretic peptide in acute hypoxemic chronic obstructive pulmonary disease[J].Clin Sci (Lond),1992,83:529-533.
10Oswald-Mammosser M,Weitzenblum E,Quoix E,et al.Prognostic factors in COPD patients receiving long-term oxygen therapy.Importance of pulmonary artery pressure[J]. Chest,1995,107:1193-1198.